Tegio, with annual sales of US $350 million, has been appraised by Qilu and Hengrui

On December 12, Hengrui pharmaceutical announced that its two specifications of tegio capsule (20mg / 25mg) passed the consistency evaluation Up to now, Hengrui pharmaceutical has invested about 15.99 million yuan in the research and development of tegio capsule project Tegio capsule was first developed by Dapeng Pharmaceutical Co., Ltd in Japan, and was first marketed in Japan in 1999 for the first-line treatment of advanced gastric cancer In 2012, tegio capsule was marketed in Denmark, Finland, Norway, Sweden and the United Kingdom, and was approved for marketing in China in 2009 According to the IMS sales database, the global sales volume of tegio capsule in 2018 is about US $380 million, and the sales volume in China is about US $350 million At present, the main manufacturers of tegio capsule in China are Hengrui pharmaceutical, Dapeng pharmaceutical, Qilu pharmaceutical and Shandong new era pharmaceutical In addition to Hengrui, Qilu pharmaceutical also announced recently that the product has passed the consistency evaluation The full text of the announcement is as follows: